New research reveals that patients who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who stop traditional lifestyle programs.
Findings released in a major health publication points out that while obese individuals often shed a large proportion of their body weight while using the jabs, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"People buying these treatments must be cognizant of the danger of rapid weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
That rate of recovery means a return to original weight within about 18 months.
Weighing Therapies
The analysis, which looked at 37 of studies involving thousands of participants, compared the effects of the injectable medications with other pills.
Scientists note that individuals who lose weight through lifestyle changes alone typically see a less rapid weight regain—around 0.1 kg a month—after stopping.
Explaining the Fast Regain
Nutrition scientists propose the way of the injections is key to understanding the accelerated rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement leads to hunger is uncontrolled, making overeating far more likely."
A Lifelong Disease?
Medical guidelines suggest the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the likelihood of relapse, the treatment should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who say that the findings "emphasize the chronic character of excess weight," comparing it to managing conditions like diabetes.
User Testimonies
Users who have come off the jabs explain a sudden return of hunger.
"I experienced a trigger flipping and you become extremely hungry," described one woman.
This challenge is compounded if patients have not established lasting dietary or behavioural modifications during therapy.
Widespread Use
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is higher among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians caution that while these medications are effective agents for weight loss, they are not a permanent fix and long-term success likely depends on ongoing behavioural changes.
